OM
SRRA

Opaleye Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Opaleye Management’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-165,778
Closed -$3.6M – 48
2021
Q4 		$3.6M Hold
165,778
– – 0.76% 32
2021
Q3 		$3.63M Buy
165,778
+278
+0.2% +$5.56K 0.68% 33
2021
Q2 		$3.22M Buy
165,500
+14,361
+10% +$261K 0.54% 41
2021
Q1 		$2.6M Buy
151,139
+75,760
+101% +$1.2M 0.38% 49
2020
Q4 		$1.21M Buy
+75,379
New +$1.05M 0.16% 51

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Opaleye Management's SRRA Position: Q1 2022 in Review

Opaleye Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2022, closing a stake of 165,778 shares — an estimated $3.6M sold.

Opaleye Management first reported a position in SRRA in Q4 2020 and held it in 5 quarters. The position peaked at $3.63M in Q3 2021. 75 funds tracked by Wall St. Rank hold SRRA as of Q1 2022.

  • Opaleye Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Opaleye Management sold 165,778 Sierra Oncology, Inc. Common Stock shares in Q1 2022, an estimated $3.6M.
  • Opaleye Management first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Opaleye Management's Sierra Oncology, Inc. Common Stock position peaked at $3.63M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2022.

Based on Opaleye Management's 13F filing for Q1 2022, filed 16 May 2022.